Insilico Medicine Taiwan Limited
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
Insilico’s flagship suite includes PandaOmics (multi-omics target identification), Chemistry42 (de novo molecular design), and InClinico (clinical outcome prediction). By leveraging these AI modules, they can rapidly generate novel molecules, predict safe
Founded Year
2018
Unified Business No.
50759371
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Insilico Medicine is a global, AI‑driven biotech company focused on generative AI for drug discovery. With headquarters in the U.S. and research facilities in Hong Kong, Taiwan, and Europe, their mission is to revolutionize drug development using their proprietary Pharma.AI platform across biology, chemistry, and clinical stages.
